[1]张晶洁,张万春,李晓敏,等.新型特异性靶向前哨淋巴结示踪剂的研究进展[J].国际放射医学核医学杂志,2018,(1):69-73.[doi:10.3760/cma.j.issn.1673-4114.2018.01.013]
　Zhang Jingjie,Zhang Wanchun,Li Xiaomin,et al.Research progress in the new specific receptor-targeted sentinel lymph node agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(1):69-73.[doi:10.3760/cma.j.issn.1673-4114.2018.01.013]
点击复制

新型特异性靶向前哨淋巴结示踪剂的研究进展(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
期数:
2018年第1期
页码:
69-73
栏目:
综述
出版日期:
2018-03-20

文章信息/Info

Title:
Research progress in the new specific receptor-targeted sentinel lymph node agents
作者:
张晶洁1;  张万春2;  李晓敏2;  马乐2
1. 030001 太原, 山西医科大学医学影像学系;
2. 030032 太原, 山西大医院核医学科
Author(s):
Zhang Jingjie1;  Zhang Wanchun2;  Li Xiaomin2;  Ma Le2
1. Department of Medical Imaging, Shanxi Medical University, Taiyuan 030001, China;
2. Department of Nuclear Medicine, Shanxi DaYi Hospital, Taiyuan 030032, China
关键词:
前哨淋巴结; 放射性药物; CD20; CD206
Keywords:
Sentinel lymph node; Radiopharmaceuticals; CD20; CD206
DOI:
10.3760/cma.j.issn.1673-4114.2018.01.013
摘要:
前哨淋巴结活检术（SLNB）广泛应用于乳腺癌、黑色素瘤等恶性肿瘤，其使用的示踪剂主要有放射性核素示踪剂和活性蓝染料，包括近年应用较多的荧光示踪剂，均为非特异性示踪剂，且存在次级淋巴结显影的问题。以B细胞表面的CD20抗原和巨噬细胞表面的甘露糖受体CD206为靶点的新型特异性靶向前哨淋巴结（SLN）示踪剂，通过放射性核素、荧光或两者共同对其进行标记，与常规示踪剂相比，其具有注射部位快速清除、SLN可快速、高摄取以及较少的远端淋巴结显影等特点，满足理想示踪剂的特性。此外，受体靶向荧光放射性药物可以实现术前放射性核素显像与术中荧光成像，研究应用于前列腺癌、结肠癌等肿瘤的SLN活检。笔者主要对新型特异性靶向SLN示踪剂的研究进展进行综述。
Abstract:
Sentinel lymph node biopsy is widely used in melanoma, breast cancer, and other malignancies. Main tracers used are radiotracers, vital blue dyes, and near-infrared fluorescent dyes; however, all have a problem with nonspecific uptake in secondary lymph nodes. The new specific-targeted sentinel node agents, which target points such as CD20 (presenting on the membrane of B lymphocytes) and CD206 (expressing on macrophages and dendritic cells), can be labeled with nuclide,fluorescence, or both. Compared with commonly used agents, these new tracers exhibit rapid clearance from the injection site, rapid uptake, high retention within the sentinel node, and low uptake by distal lymph nodes, thus satisfying the properties of an ideal lymph node imaging agent. A specific-targeted fluorescent radiopharmaceutical approach aims to apply pre-surgical nuclear imaging and intra-operative fluorescence imaging for the sentinel node localization of cancers, such as prostate and colon cancer. This article reviews and summarizes the research progress on these new specific-targeted agents.

参考文献/References:

[1] Lucci A, Mccall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011[J]. J Clin Oncol, 2007, 25(24):3657-3663.DOI:10.1200/JCO.2006.07.4062.
[2] Bluemel C, Herrmann K, Giammarile FA, et al. EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma[J]. Eur J Nucl Med Mol Imaging, 2015, 42(11):1750-1766. DOI:10.1007/s00259-015-3135-1.
[3] Wallace AM, Hoh CK, Vera DR, et al. Lymphoseek:a molecular radiopharmaceutical for sentinel node detection[J]. Ann Surg Oncol, 2003, 10(5):531-538. DOI:10.1245/ASO.2003.07.012.
[4] Cragg MS, Walshe CA, Ivanov AO, et al.The biology of CD20 and its potential as a target for mAb therapy[J]. Curr Dir Autoimmun, 2005, 8:140-174. DOI:10.1159/000082102.
[5] 王雪鹃, 杨志, 林保和,等. 前哨淋巴结显像剂99Tcm-IT-Rituximab的制备及其定位性能[J]. 中华核医学与分子影像杂志, 2006, 26(4):226-230. DOI:10.3760/cma.j.issn.2095-2848.2006.04.010. Wang XJ, Yang Z, Lin BH, et al. The preparation and localization study of a novel sentinel lymphoscintigraphy agent 99Tcm-IT-Rituximab[J]. Chin J Nucl Med Mol Imaging, 2006, 26(4):226-230. DOI:10.3760/cma.j.issn.2095-2848.2006.04.010.
[6] Stopar TG, Mlinaric-Rascan I, Fettich J, et al. Tc-99m-rituximab radiolabelled by photo-activation:a new non-Hodgkin’s lymphoma imaging agent[J]. Eur J Nucl Med Mol Imaging, 2006, 33(1):53-59. DOI:10.1007/s00259-005-1838-4.
[7] Malviya G, Anzola KL, Podestà E, et al. 99mTc-labeled rituximab for Imaging B lymphocyte infiltration in inflammatory autoimmune disease patients[J].Mol Imaging Biol, 2012, 14(5):637-646.
[8] Pandey U, Kameswaran M, Sarma HD, et al. Tc-99m carbonyl DTPA-Rituximab:Preparation and preliminary bioevaluation[J]. Appl Radiat Isot, 2014, 86(86):52-56. DOI:10.1016/j.apradiso.2013.12.036.
[9] 李艳,李囡,翟士桢,等.特异性前哨淋巴结显像剂99Tcm-rituximab药盒的制备及生物评价[J]. 同位素, 2011, 24(z1):85-89. Li Y, Li N, Zhai SZ, et al. Preparation and evaluation of a freeze-dried kit of 99Tcm-rituximab for sentinel lymph node imaging[J]. Isotopes, 2011, 24(z1):85-89.
[10] Li N, Wang XE, Lin BH, et al. Clinical evaluation of Tc-99m-Rituximab for sentinel lymph node mapping in breast cancer patients[J]. J Nucl Med, 2016, 57(8):1214-1220. DOI:10.2967/jnumed.115.160572.
[11] 丛斌斌,孙晓,宋现让,等. 新型前哨淋巴结示踪剂的制备及动物实验研究[J].中国癌症杂志, 2016, 26(3):245-250. DOI.10.3969/j.issn.1007-3969.2016.03.007. Cong BB, Sun X, Song XR,et al. The preparation and experimental study of a new sentinel lymph node tracer[J]. Chin Oncol, 2016, 26(3):245-250.
[12] Cong BB, Sun X, Song XR, et al. Preparation study of indocyanine green-rituximab:A new receptor-targeted tracer for sentinel lymph node in breast cancer[J]. Oncotarget, 2016, 7(30):47526-47535. DOI:10.18632/oncotarget.10204.
[13] 田崇麟,孙晓,刘雁冰,等. 乳腺癌前哨淋巴结活检术新型示踪剂的动物模型研究[J].中国癌症杂志,2016,26(7):569-573. DOI:10.19401/j.cnki.1007-3639.2016.07.002. Tian CL, Sun X, Liu YB, et al. The study of a novel tracer for breast cancer sentinel lymph node biopsy in an animal model[J]. Chin Oncol, 2016, 26(7):569-573.
[14] Cope FO, Abbruzzese B, Sanders J, et al. The inextricable axis of targeted diagnostic imaging and therapy:An immunological natural history approach[J]. Nucl Med Biol, 2016, 43(3):215-225. DOI:10.1016/j.nucmedbio.2015.11.007.
[15] Vera DR, Wallace AM, Hoh CK, et al. A synthetic macromolecule for sentinel node detection:99mTc-DTPA-mannosyl-dextran[J]. J Nucl Med, 2001, 42(6):951-959.
[16] Hoh CK, Wallace AM, Vera DR. Preclinical studies of[(99m)Tc]DTPA-mannosyl-dextran[J].Nucl Med Biol, 2003, 30(5):457-464. DOI:10.1016/S0969-8051(03)00028-3.
[17] 杨春慧,李洪玉,梁积新,等. 99Tcm标记右旋糖苷衍生物的制备及其生物分布[J].同位素, 2012, 25(3):149-154. Yang CH, Li HY, Liang JX,et al. Preparation and biodistribution study of 99Tcm labelled dextran conjugates[J]. Isotopes, 2012, 25(3):149-154.
[18] 李洪玉,梁积新,杨春慧,等. 99Tcm标记右旋糖苷衍生物DCM-1的淋巴结摄取和显像[J].同位素,2013,26(1):16-22. DOI. 10.7538/tws.2013.26.01.0016. Li HY, Liang JX, Yang CH, et al. Lymph nodes distribution and imaging study of 99Tcm labeled dextran conjugate DCM-1[J]. Isotopes, 2013, 26(1):16-22.
[19] Wallace AM, Hoh CK, Ellner SJ, et al. Lymphoseek:a molecular imaging agent for melanoma sentinel lymph node mapping[J]. Ann Surg Oncol, 2007, 14(2):913-921. DOI:10.1245/s10434-006-9099-4.
[20] Baker JL, Pu MY, Tokin CA, et al. Comparison of[(99m)Tc]tilmanocept and filtered[(99m)Tc]Sulfur colloid for identification of SLNs in breast cancer patients[J]. Ann Surg Oncol, 2015, 22(1):40-45. DOI:10.1245/s10434-014-3892-2.
[21] Leong SP, Kim J, Ross M, et al. A phase 2 study of (99m)Tc-Tilmanocept in the detection of sentinel lymph nodes in melanoma and breast cancer[J].Ann Surg Oncol, 2011, 18(4):961-969. DOI:10.1245/s10434-010-1524-z.
[22] Wallace AM, Han LK, Povoski SP, et al. Comparative evaluation of[99mTc]tilmanocept for sentinel lymph node mapping in breast cancer patients:results of two phase 3 trials[J]. Ann Surg Oncol, 2013, 20(8):2590-2599. DOI:10.1245/s10434-013-2887-8.
[23] Sondak VK, King DW, Zager JS, et al. Combined analysis of phase Ⅲ trials evaluating[Tc-99m]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically Node-Negative cutaneous melanoma[J]. Ann Surg Oncol, 2013, 20(2):680-688. DOI:10.1245/s10434-012-2612-z.
[24] Tokin CA, Cope FO, Metz WL, et al. The efficacy of Tilmanocept in sentinel lymph mode mapping and identification in breast cancer patients:a comparative review and meta-nalysis of the 99mTc-labeled nanocolloid human serum albumin standard of care[J]. Clin Exp Metastasis, 2012, 29(7):681-686. DOI:10.1007/s10585-012-9497-x.
[25] Ting R, Aguilera TA, Crisp JL, et al. Fast F-18 labeling of a Near-Infrared fluorophore enables positron emission tomography and optical imaging of sentinel lymph nodes[J]. Bioconjug Chem, 2010, 21(10):1811-1819. DOI:10.1021/bc1001328.
[26] Emerson DK, Limmer KK, Hall DJ, et al. A receptor-targeted fluorescent radiopharmaceutical for multireporter sentinel lymph node imaging[J].Radiology, 2012, 265(1):186-193. DOI:10.1148/radiol.12120638.
[27] Liss MA, Farshchi-Heydari S, Qin ZA, et al. Preclinical evaluation of Robotic-Assisted sentinel lymph node fluorescence imaging[J]. J Nucl Med, 2014, 55(9):1552-1556. DOI:10.2967/jnumed.114. 140871.
[28] Qin ZT, Hoh CK, Hall DJ, et al. A tri-modal molecular imaging agent for sentinel lymph node mapping[J]. Nucl Med Biol, 2015, 42(12):917-922. DOI:10.1016/j.nucmedbio.2015.07.011.
[29] Liss MA, Stroup SP, Qin ZT, et al. Robotic-assisted fluorescence sentinel lymph node mapping using multimodal image guidance in an animal model[J]. Urology, 2014, 84(4):9-14. DOI:10.1016/j.urology.2014.06.021.

相似文献/References:

[1]马乐,张万春,李晓敏.乳腺癌前哨淋巴结核素显像新进展[J].国际放射医学核医学杂志,2016,40(2):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
　Ma Le,Zhang Wanchun,Li Xiaomin.Evolution of radionuclide imaging of sentinel node lymphscintigraphy in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
[2]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
　Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
[3]甘红梅,乔晋萍,孔爱英,等.正电子放射性显像剂代谢及其研究方法进展[J].国际放射医学核医学杂志,2010,34(2):65.[doi:10.3760/cma.j.issn.1673-4114.2010.02.001]
　GAN Hong-mei,QIAO Jin-ping,KONG Ai-ying,et al.The progress on researching method and metabolism of positron radiopharmaceutical[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(1):65.[doi:10.3760/cma.j.issn.1673-4114.2010.02.001]
[4]顾涛颖,石洪成.放射性药物治疗肿瘤骨转移性骨痛的作用[J].国际放射医学核医学杂志,2010,34(2):88.[doi:10.3760/cma.j.issn.1673-4114.2010.02.006]
　GU Tao-ying,SHI Hong-cheng.The use of radiopharmaceuticals for metastatic bone pain in cancer patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(1):88.[doi:10.3760/cma.j.issn.1673-4114.2010.02.006]
[5]周雪,乔晋萍,孔爱英,等.受体结合实验及其在放射性显像剂研究中的应用进展[J].国际放射医学核医学杂志,2010,34(6):321.[doi:10.3760/cma.j.issn.1673-4114,2010.06.001]
　ZHOU Xue,QIAO Jin-ping,KONG Ai-ying,et al.Progress on the application of ligand receptor binding assays in radiopharmaceuticals[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(1):321.[doi:10.3760/cma.j.issn.1673-4114,2010.06.001]
[6]程艳,王斌全,李思进,等.SPECT-CT探测喉癌前哨淋巴结[J].国际放射医学核医学杂志,2008,32(5):268.
　CHENG Yan,WANG Bin-quan,LI Si-jin,et al.Sentinel lymph node detection by SPECT-CT in patient with laryngeal carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(1):268.
[7]李生娇,吕春堂,郭伟,等.125I标记的血管内皮生长因子受体3多抗在大鼠体内的分布研究[J].国际放射医学核医学杂志,2007,31(2):65.
　LI Sheng-jiao,LU Chun-tang,GUO Wei,et al.Study on 125I-vascular endothelial growth factor receptor-3 polyclonal antibody biod-istribution in rat[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(1):65.
[8]彭添兴,吴华.18F-氟脱氧葡萄糖以外新型PET肿瘤显像剂[J].国际放射医学核医学杂志,2007,31(1):9.
　PENG Tian-xing,WU Hua.New type PET imaging agent excluding 18F-fluorodeoxyglucose in oncology[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(1):9.
[9]刘志军.头颈部肿瘤前哨淋巴结放射性核素探测研究进展[J].国际放射医学核医学杂志,2006,30(2):91.
　LIU Zhi-jun.Detection of sentinel lymph nodes in head and neck carcinoma by lymphoscintigraphy and gamma probe[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(1):91.
[10]范我.用于肿瘤治疗的放射性药物[J].国际放射医学核医学杂志,2004,28(1):21.
　FAN Wo.Radiopharmaceuticals for tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(1):21.

备注/Memo

备注/Memo:
收稿日期:2017-11-15。
基金项目:山西省自然科学基金（2015011089）
通讯作者:张万春,Email:zhang_wanchun@126.com
更新日期/Last Update: 2018-03-20